- Home
- PCB vs CERS Comparison
PCB vs CERS Comparison
Compare PCB & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- CERS
- Stock Information
- Founded
- PCB 2003
- CERS 1991
- Country
- PCB United States
- CERS United States
- Employees
- PCB N/A
- CERS N/A
- Industry
- PCB Major Banks
- CERS EDP Services
- Sector
- PCB Finance
- CERS Technology
- Exchange
- PCB Nasdaq
- CERS Nasdaq
- Market Cap
- PCB 308.3M
- CERS 324.3M
- IPO Year
- PCB N/A
- CERS 1997
- Fundamental
- Price
- PCB $20.29
- CERS $1.58
- Analyst Decision
- PCB Hold
- CERS Buy
- Analyst Count
- PCB 2
- CERS 3
- Target Price
- PCB $22.00
- CERS $3.17
- AVG Volume (30 Days)
- PCB 27.3K
- CERS 1.0M
- Earning Date
- PCB 01-23-2025
- CERS 10-30-2024
- Dividend Yield
- PCB 3.47%
- CERS N/A
- EPS Growth
- PCB N/A
- CERS N/A
- EPS
- PCB 1.68
- CERS N/A
- Revenue
- PCB $94,833,000.00
- CERS $176,229,000.00
- Revenue This Year
- PCB N/A
- CERS $26.47
- Revenue Next Year
- PCB $10.34
- CERS $11.48
- P/E Ratio
- PCB $12.35
- CERS N/A
- Revenue Growth
- PCB N/A
- CERS 14.71
- 52 Week Low
- PCB $14.50
- CERS $1.38
- 52 Week High
- PCB $22.20
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- PCB 39.88
- CERS 38.87
- Support Level
- PCB $21.17
- CERS $1.76
- Resistance Level
- PCB $21.77
- CERS $1.83
- Average True Range (ATR)
- PCB 0.54
- CERS 0.11
- MACD
- PCB -0.18
- CERS -0.02
- Stochastic Oscillator
- PCB 9.05
- CERS 10.84
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.